• Follow the Money: Liver Cell-Reprogramming Therapy, Full-Length Dystrophin Trial, Next-Gen Neuroplastogen

    Clinical Research News | cAMPfield is launching a global phase 2b trial for moderate-to-severe ulcerative colitis and a global phase 2 for Crohn’s disease; Gero intends to advance a portfolio of both disease-modifying and aging-slowing programs in parallel; ClearNote Health continues commercial clinical study execution and broader global access; and more.

    Jul 1, 2026

  • Restoring American Leadership in Clinical Trials, University of Texas MD Anderson Joins Global Consortium, Medable’s DDF Agent

    Clinical Research News | The Ellison Medical Institute enters an exclusive license with UniQuest; TrialAssure and Cancer Research UK’s Centre for Drug Development announce new partnership; EndoDNA launches BIOS, a clinical decision-support; and more.

    Jun 30, 2026

  • India Can Surpass China in Global Pharma. But Not Where Most People Think.

    Clinical Research News | India has long been called the pharmacy of the world. That reputation was earned through manufacturing scale, generics leadership, and the ability to supply medicines globally at extraordinary volume. But the next chapter for India’s pharmaceutical industry will be different. Recent industry discussion about India’s pharmaceutical ambitions has largely explored one question: Can India compete with China as a global pharmaceutical power?

    Jun 26, 2026

  • Novo Nordisk Clinical Trial Data Targeted in Data Attack

    Clinical Research News | In mid-June Novo Nordisk announced, “an IT security incident involving unauthorized access to a limited number of internal IT systems” that exposed personal information for clinical trial participants. Novo Nordisk listed the exposed data categories as Patient ID (random alphanumeric string) and information on trial participation; sex; year of birth; biomarkers; health/immunogenicity data; and lifestyle factors including smoking, alcohol use, and BMI.

    Jun 23, 2026

  • Moving from Active to Autonomous TMF with Agentic AI

    Clinical Research News | For years, TMF leaders advocated for active TMF, a model where the TMF is a "place to go to do your work" instead of a passive archive. The shift to active TMF made significant progress for life sciences, moving toward applications that deliver real-time trial execution and TMF management. With the introduction of agentic AI in clinical trials, TMF management is now evolving from active to autonomous.

    Jun 18, 2026

  • The Invisible Infrastructure: Bio-IT World Panel Warns of a Slow-Motion Crisis in Biomedical Data

    Clinical Research News | At last month's Bio-IT World Conference & Expo, Douaa Mugahid, PhD, Data Officer at the Hi-IMPAcTB Consortium at the Harvard School of Public Health moderated a panel of academics, investors, and consultants to take on the future of public data and software infrastructure. It is time to safeguard publicly funded data infrastructure, which underpins virtually all of modern biomedical research.

    Jun 17, 2026

  • A Simple Swab Could Change How Doctors Detect Endometrial Cancer

    Clinical Research News | For the roughly 1.3 to 2 million women who visit their doctor each year with abnormal postmenopausal bleeding, the diagnostic journey has long been an uncomfortable one. The standard workup typically involves an endometrial biopsy—an invasive, often painful procedure that, despite its widespread use, fails to yield a conclusive diagnosis in more than 30% of cases. Two veteran diagnostics executives think there's a better way, and they're betting nearly $45 million in venture funding on it.

    Jun 16, 2026

  • Urine Liquid Biopsy Shows Strong Promise for Guiding Bladder Cancer Treatment — Clinical Trials on the Horizon

    Clinical Research News | A novel urine-based liquid biopsy developed at Stanford University is showing remarkable accuracy in predicting bladder cancer recurrence and may soon reshape how clinical trials enroll and treat patients. The test, developed by urologic oncologist Joseph Liao, M.D., and colleagues, filters out age-related background mutations in urine to produce a cleaner, more reliable signal for detecting residual cancer after surgery and immunotherapy.

    Jun 11, 2026

  • The Scope of Things: Measuring Equity in Cancer Care

    Clinical Research News | In the latest episode of The Scope of Things, Eugene Manley, Jr., founder and CEO of the STEMM & Cancer Health Equity Foundation, explains how underrepresented populations, including Black, Hispanic, Indigenous, rural, low-income, immigrant, underinsured, and uninsured communities, are less likely to receive guideline-aligned biomarker testing and less likely to be asked about clinical trial participation at all.

    Jun 9, 2026

  • Regulatory Outlook in Diagnostics Innovative and Uncertain

    Clinical Research News | The diagnostics industry is at the intersection of enormous clinical development and technological change, enabling first-ever detection milestones heavily driven by artificial intelligence and multi-biomarker tests. But it has increasingly been coming into conflict with a decades-old regulatory system that didn’t anticipate these technological changes and a political environment that favors U.S. competition and innovation but is also interested in cutting the budget.

    Jun 4, 2026

  • A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs

    Clinical Research News | VeriSIM Life is building the “full-stack predictive infrastructure” to help pharma companies foresee the challenges ahead in translating a molecule from laboratory discovery to a successful human therapy. The help comes in the form of a dynamic, “credit-score-like” assessment of the risk with inherent explainability and trust.

    Jun 3, 2026

  • Phesi Highlights Disconnect Between Protocols and Outcomes, Warns of AI Repetition

    Clinical Research News | An analysis released by Phesi suggests that the systematic use of historical protocol templates without using patient data and context to guide protocol design leads to flaws being scaled, rather than solved, by AI.

    Jun 2, 2026

  • Flatiron’s AI-Powered Platform, Verana Health Ovarian Cancer Database, Eir Partners Invests in QuartzBio

    Clinical Research News | uMotif launches its new Scientific Consulting Services; Veeva Systems announces Veeva Falcon; b.well Connected Health and myTomorrows announce a partnership; and more.

    May 29, 2026

  • Insider Views on the FDA’s Evolving Relationship with AI

    Clinical Research News | The Food and Drug Administration is undergoing a major step change in how it regulates and evaluates drugs, marked by a shift toward real-time clinical trials, an agency-wide rollout of generative AI tools to speed up drug application reviews, and a radical transparency push that includes public disclosure of complete response letters sent to pharmaceutical companies explaining why a drug application was rejected.

    May 27, 2026

  • Follow the Money: AI Drug Design Engine Development, Multiple Myeloma Trials, More

    Clinical Research News | Isomorphic Labs continues to develop its AI drug design engine; CellCentric advances in multiple myeloma; and more.

    May 26, 2026

  • Data is Both the Fuel and Downfall of AI in Drug Development

    Clinical Research News | High-impact opportunities for leveraging AI across the pharmaceutical R&D cycle are too numerous to count but won’t “automagically” solve any of the longstanding problems in ushering molecules to market. AI requires human attention to match tools to tasks for ensuring the accuracy of model predictions, and the pitfalls are dangerously easy to miss, according to a Novo Nordisk presentation at this week’s Scope X conference in Boston.

    May 21, 2026

  • Bacteria: Unsung Players in the Tumor Microbiome

    Clinical Research News | How cancer patients will respond to treatment can be anticipated based on their genetics as well as the tumor microenvironment, although one relevant component is often all but dismissed: the tumor microbiota. This is despite an abundance of evidence that a cancer’s microbial community plays a major role not only in therapeutic effects but also in tumor development, progression, and metastasis formation.

    May 20, 2026

  • FDA Conversation on Selective Safety Data Collection

    Clinical Research News | Earlier this month, TransCelerate BioPharma released a summary report focused on selective safety data collection (SSDC) gathered during a joint tabletop exercise convened in late 2025 in collaboration with U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER) Center for Clinical Trial Innovation (C3TI).

    May 19, 2026

  • 23andMe: How Genetics Contribute to GLP-1 Drug Outcomes

    Clinical Research News | An engaged research cohort of over 11 million genotyped individuals has enabled 23andMe to produce a library of more than 300 peer-reviewed publications over the past 16 years. Following a 2025 bankruptcy filing, when it reemerged as a nonprofit medical research organization, the focus has settled on providing individuals with access to their genetic information, supporting genetics education, and studies that provide a deeper understanding of human genetics.

    May 13, 2026

  • AI Framework for Differentiating Neurodegenerative Diseases

    Clinical Research News | A team of computational scientists at Lund University (Sweden) have built a deep, joint-learning proteomics model for improving the diagnostic accuracy for a handful of dementia-related conditions which in primary care settings remains challenging due to a shortage of informative biomarkers. Predicting these different but correlated pathologies together with a single blood test would facilitate a differential diagnosis with speed and confidence.

    May 12, 2026